Loading clinical trials...
Loading clinical trials...
A Prospective Observational Study of Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Receiving Dupilumab
Conditions
Interventions
Dupilumab
Locations
9
Italy
Investigational Site Number: 002
Bologna, Italy
Investigational Site Number: 006
Brescia, Italy
Investigational Site Number: 004
Florence, Italy
Investigational Site Number: 001
Milan, Italy
Investigational Site Number: 010
Naples, Italy
Investigational Site Number: 011
Naples, Italy
Start Date
November 30, 2023
Primary Completion Date
January 31, 2026
Completion Date
January 31, 2026
Last Updated
April 15, 2024
NCT05769777
NCT03687359
NCT03992417
NCT05983068
NCT06015308
NCT05235724
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
800-633-1610contact-us@sanofi.comLead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions